Iron Deficiency & Anemia: Symptoms, Testing & Best Supplements

Iron deficiency is the most common nutritional deficiency in the world. The World Health Organization estimates over 1.6 billion people are affected — roughly one in five humans alive right now. Yet it remains systematically underdiagnosed, partly because the symptoms are nonspecific (fatigue, brain fog, poor exercise tolerance), and partly because most people and many clinicians conflate iron deficiency with iron deficiency anemia. These are not the same thing. The distinction has significant clinical consequences.

Iron deficiency exists on a spectrum. At one end: depleted iron stores with a low ferritin but normal hemoglobin. At the other: full iron deficiency anemia with impaired red blood cell production and measurably low hemoglobin. Most people don't reach anemia before they've spent months or years in the subclinical deficiency zone — experiencing real, measurable functional impairment with iron stores that are too low to support optimal physiology, yet not low enough to trigger an anemia diagnosis on a standard CBC.

This guide covers the full spectrum: how iron works in the body, what deficiency looks like before anemia, how to test properly, which supplement forms actually absorb, and — critically — who should not supplement iron without confirmed bloodwork.

This article is for informational purposes only and is not medical advice. Consult a qualified healthcare provider before making changes to your supplementation or health regimen, particularly for a mineral with meaningful toxicity risk at excessive doses.

What Iron Actually Does: More Than Just Red Blood Cells

Most people learn about iron in the context of hemoglobin — the protein in red blood cells that binds oxygen and carries it from the lungs to tissues throughout the body. This is accurate but incomplete. Iron is a fundamental cofactor in dozens of biological processes, and understanding this broader role explains why iron deficiency produces such a wide range of symptoms long before the red blood cell count drops.

Hemoglobin and oxygen transport. Each hemoglobin molecule contains four heme groups, each with an iron atom at its center. Iron's unique chemistry allows it to reversibly bind oxygen — picking it up in the oxygen-rich environment of the lungs and releasing it in the lower-oxygen environment of metabolically active tissues. Without sufficient iron, the body produces fewer functional red blood cells and hemoglobin concentration falls. The result is reduced oxygen delivery to every tissue in the body.

Myoglobin and muscle oxygen storage. Myoglobin is the muscle analog to hemoglobin — an iron-containing protein that stores and releases oxygen within muscle cells to support aerobic metabolism during exercise. Iron deficiency depletes myoglobin stores, directly impairing muscle endurance and exercise tolerance. This is why endurance athletes are disproportionately affected by iron deficiency: even mild depletion measurably reduces VO2 max and time-to-exhaustion before hemoglobin levels fall enough to trigger clinical anemia.

Mitochondrial energy production. Iron is a structural component of the cytochrome enzyme complexes in the mitochondrial electron transport chain — the molecular machinery that converts oxygen and fuel substrates into ATP. This is one reason why fatigue in iron deficiency isn't simply explained by reduced oxygen delivery; the cellular machinery for producing energy is itself compromised.

Cognitive function and neurotransmitter synthesis. Iron is required for the synthesis of dopamine, serotonin, and norepinephrine — major neurotransmitters involved in motivation, mood, and executive function. Iron-dependent enzymes (tyrosine hydroxylase, tryptophan hydroxylase) catalyze rate-limiting steps in these pathways. This explains the cognitive symptoms of iron deficiency — difficulty concentrating, low motivation, emotional blunting — which can precede anemia by months.

Immune function. Iron is required for the proliferation and maturation of immune cells, including T lymphocytes and natural killer cells. Iron deficiency impairs cell-mediated immunity and increases susceptibility to infection. Counterintuitively, iron is also essential for pathogen survival, which is why the body's acute-phase response to infection includes sequestering iron away from pathogens — temporarily mimicking the lab picture of iron deficiency.

The Deficiency Spectrum: From Low Ferritin to Frank Anemia

Iron deficiency progresses through three stages, each with distinct lab findings and clinical consequences:

Stage 1: Iron depletion. Ferritin (the storage protein) falls below optimal levels — typically defined as <30 ng/mL, though some researchers place the functional threshold closer to <50 ng/mL for active individuals. Serum iron and hemoglobin remain normal. Transferrin saturation may be mildly reduced. Symptoms at this stage are subtle but real: mild fatigue, reduced exercise tolerance, occasional difficulty concentrating. Standard screening (CBC alone) will miss this entirely.

Stage 2: Iron-deficient erythropoiesis. Iron stores are sufficiently depleted that red blood cell production begins to be affected. Transferrin saturation falls below 15–20%. The body produces red blood cells that are increasingly small and pale (microcytic, hypochromic). Hemoglobin may still fall within the "normal" reference range, but is lower than the individual's baseline. Symptoms become more prominent: persistent fatigue, decreased aerobic performance, difficulty with sustained mental effort.

Stage 3: Iron deficiency anemia. Hemoglobin falls below the clinical threshold (12 g/dL in women, 13 g/dL in men per WHO criteria). Mean corpuscular volume (MCV) is low; red cells are visibly microcytic and hypochromic on a blood smear. Symptoms are often severe: profound fatigue, exertional dyspnea, palpitations, pallor, brittle nails, hair loss, and in severe cases the phenomenon of pica (craving for ice, clay, or other non-food substances). At this stage the diagnosis is unmistakable — but a significant opportunity for earlier intervention has been missed.

The practical implication: ferritin is the most sensitive early marker of iron status, and it is often not included in standard blood panels. Specifically requesting ferritin is essential for anyone with risk factors or symptoms, even if the CBC comes back "normal."

Who Is at Risk: The High-Prevalence Groups

Iron deficiency is not evenly distributed. Certain populations face structural disadvantages in maintaining adequate iron status — from higher physiological requirements, to lower absorption from plant-heavy diets, to ongoing losses that exceed dietary intake.

Premenopausal women. Menstruation is the dominant risk factor for iron deficiency in women of reproductive age. A typical menstrual cycle results in 10–80 mL of blood loss, equating to 5–40 mg of iron — a meaningful fraction of the monthly iron budget for most women. Heavier menstrual bleeding (menorrhagia) amplifies this considerably. The WHO estimates iron deficiency affects approximately 30–40% of premenopausal women globally. In women with heavy periods, the figure is substantially higher.

Pregnant and postpartum women. Pregnancy dramatically increases iron requirements — estimated at 1,000 mg additional iron over the course of a full-term pregnancy to support fetal development, placental growth, and expanded maternal red cell mass. The RDA rises to 27 mg/day during pregnancy (from 18 mg in non-pregnant women). Postpartum blood loss adds to the deficit. Iron deficiency during pregnancy is associated with preterm birth, low birth weight, and impaired neonatal neurodevelopment.

Endurance athletes. Distance runners and cyclists face iron depletion through multiple mechanisms: foot-strike hemolysis (red cell destruction from repeated impact), GI blood loss (a documented consequence of intense endurance training), increased iron losses in sweat, and elevated requirements driven by high red cell turnover. Studies have found iron deficiency in 15–35% of female endurance athletes and 5–11% of males — with functional impairment beginning well before clinical anemia.

Vegans and vegetarians. Plant foods contain only non-heme iron (see the section on absorption below), which absorbs significantly less efficiently than heme iron from animal sources. Additionally, plant-heavy diets are often high in phytates and polyphenols, which further inhibit non-heme absorption. The RDA for vegetarians is set at 1.8 times that of omnivores specifically to account for lower bioavailability.

Frequent blood donors. Each whole blood donation removes approximately 200–250 mg of iron. Regular donors — particularly women — are at meaningful risk of progressive iron depletion if dietary intake and recovery time are insufficient between donations.

People with GI conditions. Celiac disease, inflammatory bowel disease, and gastric bypass surgery all impair iron absorption. Chronic GI blood loss from ulcers, polyps, or colorectal cancer is a major cause of iron deficiency in older adults and men — and unexplained iron deficiency in a postmenopausal woman or any adult man warrants GI investigation before iron supplementation is started.

Heme vs. Non-Heme Iron: Why the Source Matters

Dietary iron comes in two chemically distinct forms, and the difference in bioavailability is substantial enough to be practically important for anyone relying on plant sources.

Heme iron is found exclusively in animal products — meat, poultry, and seafood. It is iron bound within the porphyrin ring of hemoglobin and myoglobin. The GI tract absorbs heme iron through a dedicated receptor-mediated pathway (HCP1/PCFT) that is largely independent of the dietary context. Absorption rates typically range from 15–35%, and are not significantly affected by other foods consumed in the same meal. Heme iron is simply the most efficient dietary source available.

Non-heme iron is found in plant foods (legumes, fortified grains, dark leafy greens, nuts, seeds) and also in animal products beyond the muscle meat. It must first be reduced from ferric iron (Fe³⁺) to ferrous iron (Fe²⁺) in the gut before absorption via the DMT1 transporter. This process is highly sensitive to the surrounding dietary environment. Absorption rates range widely — 2–20% — and are dramatically affected by enhancers and inhibitors consumed in the same meal.

The most important enhancer is vitamin C (ascorbic acid). In a landmark series of studies, Hallberg and colleagues (1987) demonstrated that 25–75 mg of vitamin C consumed with a non-heme iron meal could increase non-heme absorption by 2–4 fold. The mechanism is direct chemical reduction of Fe³⁺ to the more absorbable Fe²⁺, and chelation that keeps iron soluble in the alkaline environment of the small intestine. A glass of orange juice with iron-rich plant foods is not just tradition — it has quantifiable biological benefit.

The most important inhibitors include:

• Phytates (phytic acid) — found in grains, legumes, and seeds. Bind iron in the intestinal lumen, forming insoluble complexes that cannot be absorbed. Soaking, sprouting, and fermentation reduce phytate content.
• Polyphenols and tannins — found in tea, coffee, red wine, and many plant foods. Even moderate tea or coffee consumption with a meal can reduce non-heme absorption by 60–80%. Timing matters: consuming tea an hour before or after a meal significantly reduces inhibition.
• Calcium — inhibits both heme and non-heme iron absorption, likely by competing for the DMT1 transporter. Taking calcium supplements or consuming high-dairy meals with iron-rich foods or iron supplements reduces iron absorption. Separating calcium and iron intake by 1–2 hours is consistently recommended.

Iron Supplement Forms: What the Evidence Actually Shows

The supplement market offers several iron forms with meaningfully different profiles for absorption, tolerability, and cost. The choice matters, particularly for people who need to supplement long-term or who have experienced GI side effects with standard iron products.

Ferrous sulfate is the most widely studied, most widely prescribed, and cheapest form of supplemental iron. It delivers elemental iron efficiently — absorption is well established across decades of clinical use. The main limitation is GI tolerability: nausea, constipation, abdominal cramping, and darkened stools are common, especially at higher doses. These side effects are the primary reason for non-adherence in iron repletion therapy. Ferrous sulfate taken with food reduces GI effects but also reduces absorption.

Ferrous gluconate and ferrous fumarate are alternative ferrous (Fe²⁺) salts that may be slightly better tolerated than ferrous sulfate at equivalent elemental iron doses, though the evidence for meaningfully superior tolerability is mixed. Ferrous fumarate has a higher percentage of elemental iron by weight than sulfate or gluconate, which affects dosing math.

Ferrous bisglycinate (iron glycinate chelate) is the most evidence-supported premium form. In this chelated compound, ferrous iron is bound to two glycine molecules, protecting it from interactions with dietary inhibitors and allowing it to be absorbed through a different pathway (peptide transporters) alongside the standard DMT1 route. Milman and colleagues (2014) found equivalent iron repletion efficacy between ferrous bisglycinate and ferrous sulfate in pregnant women, with significantly fewer GI side effects in the bisglycinate group. A meta-analysis by Jimenez et al. (2010) similarly demonstrated superior tolerability with comparable or superior absorption efficiency. The practical implication: ferrous bisglycinate can often be taken on an empty stomach (where absorption is highest) without the GI distress that limits compliance with ferrous sulfate.

Iron polysaccharide complex (IPC) is a non-ionic form of iron in which ferric iron is complexed with polysaccharides. It is often marketed as "gentle iron." Tolerability is generally good, but absorption data are inconsistent — some studies suggest significantly lower bioavailability compared to ferrous forms, while others show comparable efficacy. The variable absorption profile makes it less predictable for repletion therapy.

Carbonyl iron is a highly purified, elemental iron in microscopic particles. Its slower dissolution rate results in gradual absorption and reduced peak serum iron concentrations, which appears to reduce GI side effects and may lower the risk of acute toxicity. Absorption is adequate but slightly lower than ferrous forms. It may be a reasonable option for those who cannot tolerate other forms.

Dosing: RDA, Therapeutic Doses, and the Every-Other-Day Protocol

Iron dosing varies considerably depending on whether the goal is maintenance (meeting daily requirements) or repletion (replenishing depleted stores). Getting this right matters — both underdosing (insufficient to correct deficiency) and overdosing (contributing to GI problems and potentially iron overload) have real consequences.

Dietary Reference Intakes (RDA):

• Adult men (19–50): 8 mg/day elemental iron
• Adult women (19–50): 18 mg/day
• Pregnant women: 27 mg/day
• Women 51+: 8 mg/day (postmenopausal; equivalent to men)
• Vegetarians: 1.8× the above values (14.4 mg for adult men, 32.4 mg for premenopausal women)

Therapeutic doses for iron deficiency correction are substantially higher — typically 50–200 mg elemental iron per day, depending on the severity of deficiency, the form used, and clinical supervision. Standard medical treatment often involves 150–200 mg elemental iron daily in divided doses, though evidence increasingly supports lower doses (e.g., 50–60 mg) as similarly effective with significantly fewer side effects.

The every-other-day dosing protocol is one of the most practically important advances in iron supplementation in recent years, supported by the work of Stoffel and colleagues published in 2017 in The Lancet Haematology. The underlying mechanism involves hepcidin — a liver-produced hormone that regulates intestinal iron absorption. When a dose of iron is absorbed, hepcidin rises transiently over the next 24 hours, causing a temporary downregulation of iron absorption. Taking iron on consecutive days means that the second dose arrives during peak hepcidin elevation, significantly reducing how much is absorbed. By dosing every other day, the second dose arrives when hepcidin has returned to baseline — maximizing total absorbed iron while reducing cumulative dose and GI exposure. In Stoffel's study, every-other-day dosing resulted in 40% higher fractional iron absorption compared to consecutive daily dosing in iron-depleted women, with substantially fewer GI complaints.

The clinical implication is that 60 mg every other day may outperform 100 mg daily in both total iron absorbed and side effect burden — a counterintuitive but well-supported finding that should inform how most people approach supplementation.

Critical: Who Should NOT Supplement Without Testing

This is not a pro forma warning. Iron is a mineral with genuine toxicity risk — and the population most likely to self-supplement "just in case" includes demographics where iron overload is a serious concern.

Men and postmenopausal women should not supplement iron without confirmed deficiency. Unlike premenopausal women who lose iron monthly through menstruation, men and postmenopausal women have no physiological mechanism for iron excretion beyond the small losses in sweat, skin cells, and GI mucosal cells. If iron intake persistently exceeds these losses, iron accumulates. Hereditary hemochromatosis — a genetic condition causing excessive iron absorption — affects approximately 1 in 200–300 people of Northern European descent, making it one of the most common genetic disorders in this population. Many carriers are undiagnosed. Iron supplementation in a person with undiagnosed hemochromatosis accelerates tissue iron deposition and organ damage.

Even without hemochromatosis, iron accumulation over time is associated with increased oxidative stress, cardiovascular risk, liver damage, and some evidence linking elevated iron stores to increased risk of colorectal cancer. Iron is a pro-oxidant — it catalyzes the Fenton reaction, generating hydroxyl radicals from hydrogen peroxide. In excess, this oxidative activity damages cells.

Unexplained iron deficiency in adult men or postmenopausal women warrants GI investigation before supplementation begins. In these groups, iron deficiency is unusual and typically indicates blood loss from a GI source — ulcer, polyp, or colorectal malignancy. Supplementing iron without identifying the source delays diagnosis of potentially serious underlying pathology.

Understanding Your Iron Panel: What to Test and What the Numbers Mean

A complete iron status assessment involves several markers, not just hemoglobin. Understanding what each measures helps you interpret results and have informed conversations with healthcare providers.

Ferritin is the primary iron storage protein and the most sensitive early marker of iron depletion. Lab reference ranges often list anything above ~12 ng/mL as "normal," but functional thresholds based on symptom and outcome data are substantially higher. Ferritin <30 ng/mL is widely used as a threshold for depleted stores in athletes and symptomatic individuals; some clinicians use <50 ng/mL for active people. Elevated ferritin, conversely, can indicate iron overload — but is also an acute-phase reactant that rises with inflammation, masking true iron status in people with chronic inflammatory conditions.

Serum iron measures circulating iron in transit in the blood. It is highly variable — fluctuating with recent meals, time of day, and stress — making it a poor standalone marker. It is most useful in context with other measures.

Total iron binding capacity (TIBC) and transferrin saturation. Transferrin is the transport protein that carries iron in the bloodstream. TIBC measures the total iron-binding capacity of transferrin (a proxy for transferrin concentration). Transferrin saturation (serum iron ÷ TIBC × 100) indicates what percentage of available binding sites are occupied with iron. Normal saturation is approximately 20–50%. Saturation <15–16% indicates insufficient iron supply for red cell production even when ferritin is borderline.

Hemoglobin and mean corpuscular volume (MCV) are standard CBC components. Low hemoglobin with low MCV (microcytic anemia) is the classic pattern of iron deficiency anemia — but remember, these are late-stage findings. Normal hemoglobin and MCV do not rule out iron deficiency.

The most useful combination for assessment: ferritin + transferrin saturation (TIBC + serum iron) + CBC. Ask for these specifically — most standard annual labs only include CBC.

The B12-Folate Connection: When Anemia Isn't All About Iron

Not all anemia is iron deficiency anemia, and this distinction is clinically important because supplementing the wrong nutrient in the wrong type of anemia can delay treatment and in some cases cause harm.

Vitamin B12 and folate deficiency produce a macrocytic anemia — characterized by large, immature red cells (high MCV) rather than the small red cells of iron deficiency. The underlying mechanism is impaired DNA synthesis: both B12 and folate are required for the methylation chemistry that produces thymidine, a DNA base. Without it, rapidly dividing cells like red blood cell precursors cannot complete cell division properly, producing abnormally large cells with short lifespans.

In practice, mixed deficiencies exist — a vegan who is both iron-deficient and B12-deficient may have a "normal" MCV because microcytic and macrocytic signals cancel each other out. This is one reason ferritin, B12, and folate should all be tested when investigating unexplained fatigue or poor exercise tolerance, particularly in vegans, vegetarians, older adults, and people with GI conditions. See our Vitamin B Complex guide for the full picture on B12 and B-vitamin metabolism.

Iron Buyer's Checklist

If you've confirmed iron deficiency through testing and are selecting a supplement, these criteria narrow the field significantly:

• Ferrous bisglycinate preferred. Best evidence for GI tolerability with equivalent efficacy. Look for 18–36 mg elemental iron per serving for maintenance; therapeutic doses may require higher amounts under medical supervision.
• Third-party tested. Look for NSF Certified for Sport, USP Verified, or Informed Sport certification. Iron content can vary substantially from label claims in uncertified products.
• Take on an empty stomach when possible. Absorption peaks without food. If GI symptoms occur, try ferrous bisglycinate specifically (better tolerated on an empty stomach than ferrous sulfate), or take with a small amount of food that does not contain calcium, phytates, or polyphenols.
• Pair with vitamin C. Take 100–200 mg of vitamin C alongside iron (from supplement or food source) to maximize non-heme iron absorption.
• Separate from calcium, coffee, and tea by at least 1–2 hours. These are the three most consistent absorption inhibitors.
• Consider every-other-day dosing. Particularly if taking 60 mg or more elemental iron daily — the every-other-day protocol improves total absorbed iron while reducing side effects.
• Retest ferritin at 3 months. Confirm stores are replenishing. Correction of severe deficiency typically takes 3–6 months even with consistent supplementation.

For the broader picture of building a complete supplement foundation — and how iron fits into the micronutrient stack alongside vitamin D, B12, and magnesium — see our Complete Supplement Stack Guide. For the vitamin D deficiency parallel (common in the same demographic as iron deficiency, and often co-occurring), see our Vitamin D guide.